Quintara Discovery, Inc. has been acquired by Frontage Laboratories, Inc.
QDI Advantages
At QDI, we have accumulated extensive knowledge and insight in designing high-fidelity assays, obtaining and analyzing critical data, and prioritizing compounds to advance to the next discovery and development stage. All experiments are performed in California by an experienced and talented scientific team with a proven track record. Our scientists and project managers are always available for real-time communication, discussion, and consultation.
Quality: core competency, extensive QC, attention to details
Depth: extensive know-how, trouble shooting, experimental design, streamlined operation and versatile, flexible platform
Integrity: focus on customer needs, data quality, attention to quality, and turn-around time of the data
Sense of community: Integration into client’s team, communication in real-time
Proven Record
We have a proven record of bringing success to our clients and their projects by an intense and undivided focus on experiments and compound profiling. In the past 6 years, QDI has achieved and demonstrated the following:,
- Working with over 250 organizations, including 6 of the 10 largest biopharma companies in the world;
- Collaborating with many leading universities and institutes such as Stanford, UCSF, Harvard, NIH and NCI;
- Supporting numerous start-up companies that have undergone IPO or been bought by large pharma/biotech companies. Some of our clients were acquired at a significant premium by larger pharma and biotech firms such as AbbVie, Allergan, Amgen, Merck, Pfizer, and Roche/Genentech;
- Providing data to support the successful filings of various INDs, NDA’s and BLA’s of both small and large molecules
Capabilities
A talented scientific team who have extensive knowledge and insight in designing high-fidelity assays, obtaining and analyzing critical data, and prioritizing compounds for advancement
Modern, spacious facility with approximately 18,000 sf.
State-of-the-art equipments and robust & flexible workflow: label-free detection with Thermo QE ORBITRAP HRMS, API 5000, 4000 and 4000 Q-Trap, multiple liquid handling stations, and versatile plate-readers
Our strong focus on lab operation, automation, instrumentation and project management enables an industry-leading turn-around time with excellent quality. We stand behind all our assay results. With a customer-centric philosophy, QDI strives to be your partner in Drug Discovery & Development!
Meet Our Team
Our founders have over 50 years of combined drug discovery and development experience. In our own research efforts, we have successfully progressed over 20 compounds into clinical trials, including two FDA-approved cancer drugs. In supporting our clients, we have helped multiple successful NDA and BLA filings as well as numerous IND studies.
Wentao Zhang, Ph.D.
Founder & President
Wentao has 20 years of industry experience in drug discovery and preclinical development. He has evaluated over 200 drug targets and helped progress over 20 compounds from discovery to clinical development, including candidates in phase 2 and 3 clinical trials and Cometriq™, a kinase inhibitor approved for medullary thyroid cancer by the FDA. Prior to founding Quintara Discovery in 2012, Wentao was Senior Director of New Lead Discovery at Exelixis, managing key drug discovery platforms and functions that included compound collection, lead discovery and optimization, and in vitro ADME. Wentao is an ad hoc member of the NIH study section on assay development & HTS, and served as President of Chinese American Biopharmaceutical Society 2012-13. He has authored and co-authored discovery data package (biology) and preclinical DMPK study reports for IND and NDA filings, as well as 30 scientific publications. Wentao obtained his Ph.D. degree from the University of Wisconsin-Madision and did post-doctoral research at the University of California-Berkeley.
Sean Xiang Wu, Ph.D.
Co-Founder & Head of Discovery Services
Sean has extensive experience in drug discovery and most recently was Associate Director at Exelixis, leading a team of scientists for ADME profiling of all discovery and development compounds. Sean is extremely versatile in optimizing various ADME assays to improve data quality and reproducibility, and utilizing automation in liquid handling and data analysis to improve assay throughput. At Exelixis, he represented and provided DMPK guidance in over 10 cross-functional project teams, including all ADME support for Cometriq™. He has served as an editorial board member of Journal of Biomolecular Screening. Sean obtained his Ph.D. degree from Georgia Health Sciences University and did post-doctoral research at Yale University and Novartis Pharmaceuticals.
Julie Ren, Ph.D. Co-Founder & Head of BA and Preclinical Development
Julie has over 19 years of industry experience in drug discovery and development, most recently as Director, Bioanalytical, Nonclinical Development (DMPK) at Exelixis. Julie led the discovery bioanalysis and pharmacokinetics, conducting and managing pharmacokinetics, toxicokinetics, PK/PD, PK/efficacy, drug distribution, metabolite identification, and cellular uptake evaluations for lead validation and optimization at Exelixis. She also established and managed the GLP bioanalytical laboratory in supporting non-clinical toxicokinetics, clinical pharmacokinectics, metabolism, drug-drug interaction and bioequivalence studies for over twenty IND and one NDA filings. Julie has participated in multiple successful FDA audits. Julie obtained her Ph.D. from University of Alabama and did post-doctoral research at University of California, San Francisco.
